Gastralgia dispersed tablet and preparation

A dispersible tablet and prescription technology, applied in the field of Anwei dispersible tablet and its preparation, can solve problems such as difficulty in taking, unable to meet the medication needs of patients with acute epigastric pain, and slow disintegration speed

Inactive Publication Date: 2008-11-05
福建省医学科学研究所
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disintegration speed of the tablet is slow, and it is difficult for the elderly, children and patients with dysphagia to take it; it cannot meet the medication needs of patients with acute epigastric pain; and because it contains a large amount of sea octopus, patients feel fishy when taking it Strong smell, prone to nausea and vomiting; at the same time, the quality standard can be further improved. Based on this, we use modern pharmaceutical technology to make necessary improvements to the product process, form a new preparation, and improve quality control standards to ensure product monitoring. Quality, benefit the people

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gastralgia dispersed tablet and preparation
  • Gastralgia dispersed tablet and preparation
  • Gastralgia dispersed tablet and preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Orthogonal experiment to optimize the granulation process of Anwei Dispersible Tablets

[0029] Orthogonal experimental design and results

[0030] Investigate the four factors of the relative percentages of PVPP, PVP, CMS-Na and MCC in the used excipients (that is, the percentage of the excipients used in the total amount of excipients in the prescription), and use the dispersion uniformity as the investigation index to determine the amount of each excipient , the results are shown in Table 1 to Table 3 below.

[0031] Table 1 Experimental factor level table

[0032]

[0033] Table 2 Intuitive analysis results

[0034]

[0035] Table 3 ANOVA results

[0036]

[0037] *Indicates that the factor is significant.

[0038] From the above results, it can be seen that the four factors affecting the tablet granulation process are: PVPP>PVP>MCC>CMS-Na, the optimal granulation process conditions: A 2 B 1 C 2 D. 3 , namely PVPP21%, PVP6%, MCC40%, CMS-Na...

Embodiment 2

[0039] Example 2 The best implementation of this invention is: the three herbs in the prescription are tested and qualified respectively for future use; vinegar-made corydalis (10.50%), shelled sea octopus (41.67%), calcined alum (31.17%), and cross-linked Polyvinylpyrrolidone (3.50%), microcrystalline cellulose (6.67%), sodium lauryl sulfate (2.17%), sodium carboxymethyl starch (3.33%) are mixed evenly, with polyvinylpyrrolidone (1%) as the viscosity The mixture is used to prepare soft materials, granulated with a No. 2 sieve, dried at 60°C, sized with a No. 2 sieve, and compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a dispersible gastralgia tablet and a preparation method thereof, the invention carries out the technological reform of the formulation based on the existing ordinary tablets, thus overcoming the shortcomings of heavier fishy smell, difficult administration, slow speed of disintegration and slow onset of action of the original formulation, enriching the types of the drugs, improving the quality standards and further meeting and ensuring the demands on the drugs by the people. The drug has the effects of activating qi-flowing, activating blood circulation, inhibiting acid and stopping pain, which is used for gastralgia, acid regurgitation, belching eructation and epigastric distension caused by qi-stagnancy and blood stasis, as well as gastric and duodenal ulcers and chronic gastritis with the symptoms. The efficacy is significant. The usage and carrying are convenient, which is a clinically popular, safe, stable and effective drug and an ideal product for the modern pharmaceutical enterprises.

Description

technical field [0001] The invention relates to the technical field of preparation technology of Chinese patent medicine dispersible tablets, in particular to Anwei dispersible tablets and a preparation method thereof. Background technique [0002] Dispersible tablets refer to tablets that can quickly disintegrate and evenly disperse in water. Traditional Chinese medicine dispersible tablets are made of traditional Chinese medicine extracts, traditional Chinese medicine raw powder or refined intermediates, plus suitable auxiliary materials, and can be dissolved in water. Rapidly disintegrates uniformly dispersed tablets. Dispersible tablets originated from the "British Pharmacopoeia", which refers to a new tablet dosage form that rapidly disintegrates in water to form a uniform suspension. Ordinary tablets often affect the full absorption of drugs due to disintegration and slow drug dissolution, and the elderly, children, and patients with dysphagia often have difficulty ta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/66A61K9/20A61K47/38A61P1/04A61P1/14A61K33/06A61K35/56A61K35/618
Inventor 林文津徐榕青张亚敏林凌
Owner 福建省医学科学研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products